Core Insights - Polyrizon Ltd. has initiated a key usability study for its lead product candidate, NASARIX™, aimed at confirming alignment with FDA requirements and supporting clinical development [1][2] Group 1: Product Development - NASARIX™ is an innovative intranasal allergy blocker designed for broad consumer use, representing a significant advancement in Polyrizon's development roadmap [1][2] - The usability study is intended to de-risk downstream regulatory review and facilitate a streamlined path toward clinical trials [2][3] Group 2: Regulatory Milestones - Successful completion of the usability program will provide essential regulatory evidence for NASARIX™'s readiness for clinical evaluation, with trials expected to commence in Q3 2026 [3][4] - The study underscores the company's commitment to FDA-aligned development, patient safety, and user-centered solutions [4] Group 3: Company Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The proprietary Capture and Contain™ hydrogel technology aims to function as a "biological mask" in the nasal cavity, with ongoing development focused on enhancing bioadhesion and retention [4]